Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:lapatinib
go back to main search page
Accession:CHEBI:49603 term browser browse the term
Definition:A furan that has formula C29H26ClFN4O4S.
Synonyms:exact_synonym: N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
 related_synonym: Formula=C29H26ClFN4O4S;   GW 572016;   InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35);   InChIKey=BCFGMOOMADDAQU-UHFFFAOYSA-N;   N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine;   N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE;   SMILES=CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1;   Tykerb
 alt_id: CHEBI:38636;   CHEBI:49602;   MESH:C490728
 xref: Beilstein:10502247;   CAS:231277-92-2;   DrugBank:DB01259;   Drug_Central:1548;   LINCS:LSM-1051
 xref_mesh: MESH:C490728
 xref: PDBeChem:FMM;   Wikipedia:Lapatinib


show annotations for term's descendants           Sort by:
lapatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO lapatinib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 PMID:28437613 NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] CTD PMID:18829547 NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO lapatinib results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:26,106,895...26,164,440 JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate] CTD PMID:18829547 NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein] CTD PMID:26643609 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity
decreases phosphorylation 		ISO [Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form
lapatinib results in decreased activity of AKT1 protein
Lapatinib results in decreased phosphorylation of AKT1 protein 		CTD PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 More... NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein CTD PMID:26643609 NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions 		ISO Lapatinib results in increased expression of BAX protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]] 		CTD PMID:29387217 PMID:32890875 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions 		ISO Lapatinib results in decreased expression of BCL2 protein
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]] 		CTD PMID:29387217 PMID:32890875 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO lapatinib results in decreased expression of BIRC5 protein CTD PMID:16091755 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] CTD PMID:25981168 NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962 		JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity 		ISO Lapatinib results in increased cleavage of CASP3 protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]
Lapatinib results in increased activity of CASP3 protein 		CTD PMID:29387217 PMID:32890875 PMID:37788138 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732 		JBrowse link
G Casp7 caspase 7 increases activity ISO Lapatinib results in increased activity of CASP7 protein CTD PMID:37788138 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
increases activity 		ISO 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein]
Lapatinib results in increased activity of CASP9 protein 		CTD PMID:29387217 PMID:37788138 Ensembl chr 5:159,391,188...159,409,648 JBrowse link
G Ccna2 cyclin A2 decreases expression ISO lapatinib results in decreased expression of CCNA2 protein CTD PMID:25221644 NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression 		ISO [afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]
lapatinib results in decreased expression of CCND1 protein 		CTD PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810 		JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] CTD PMID:15665275 NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822 		JBrowse link
G Cd24 CD24 molecule multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein CTD PMID:26643609 NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785 		JBrowse link
G Cd44 CD44 molecule multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]] CTD PMID:26643609 PMID:33396024 NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO [Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein] CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein] CTD PMID:26643609 NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO [afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] CTD PMID:15665275 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] CTD PMID:32890875 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression 		ISO [afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
lapatinib results in increased expression of CDKN1B protein 		CTD PMID:15665275 PMID:20701607 PMID:32890875 NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity
increases metabolic processing 		ISO Lapatinib results in decreased activity of CYP1A1 protein
CYP1A1 protein results in increased metabolism of Lapatinib 		CTD PMID:33814510 PMID:37788138 NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Lapatinib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
multiple interactions 		ISO CYP3A4 protein results in increased metabolism of Lapatinib
[CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA 		CTD PMID:26958860 PMID:33259822 PMID:37788138 NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases metabolic processing
multiple interactions 		ISO CYP3A5 protein results in increased metabolism of Lapatinib
[CYP3A5 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein] 		CTD PMID:26958860 PMID:37788138 NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154 		JBrowse link
G Egfr epidermal growth factor receptor decreases activity
multiple interactions
affects response to substance 		ISO lapatinib results in decreased activity of EGFR protein
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] 		CTD PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874 NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases activity
decreases expression
decreases phosphorylation 		ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
lapatinib results in decreased activity of ERBB2 protein
lapatinib results in decreased expression of ERBB2 protein
lapatinib results in decreased phosphorylation of ERBB2 protein 		CTD PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 More... NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 decreases expression
decreases activity 		ISO lapatinib results in decreased expression of ERBB3 protein modified form
lapatinib results in decreased activity of ERBB3 protein 		CTD PMID:19435893 PMID:19509167 NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120 		JBrowse link
G Esr1 estrogen receptor 1 decreases activity
multiple interactions 		ISO lapatinib results in decreased activity of ESR1 protein
[lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein 		CTD PMID:15665275 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Lapatinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160 		JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions 		ISO Lapatinib results in increased expression of H2AX protein
CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]; CYP3A7 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein] 		CTD PMID:37788138 NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]] CTD PMID:25981168 PMID:32890875 NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression 		ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA
lapatinib metabolite results in increased expression of HMOX1 mRNA 		CTD PMID:26958860 NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818 		JBrowse link
G Jak2 Janus kinase 2 multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein] CTD PMID:32890875 NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762 		JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases response to substance
multiple interactions 		ISO KRAS protein results in decreased susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib] 		CTD PMID:28739874 NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320 		JBrowse link
G Ldha lactate dehydrogenase A increases secretion ISO Lapatinib results in increased secretion of LDHA protein CTD PMID:37660997 NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases activity
decreases expression
decreases phosphorylation 		ISO ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
lapatinib results in decreased activity of MAPK1 protein
lapatinib results in decreased expression of MAPK1 protein
lapatinib results in decreased phosphorylation of MAPK1 protein 		CTD PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More... NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 multiple interactions ISO lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]] CTD PMID:28739874 NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases activity
decreases expression
decreases phosphorylation 		ISO ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
lapatinib results in decreased activity of MAPK3 protein
lapatinib results in decreased expression of MAPK3 protein
lapatinib results in decreased phosphorylation of MAPK3 protein 		CTD PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More... NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 multiple interactions
decreases expression 		ISO ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein] CTD PMID:25221644 NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein] CTD PMID:26643609 NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases activity 		ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein
lapatinib metabolite results in increased activity of NFE2L2 protein 		CTD PMID:26958860 NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression 		ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA
lapatinib metabolite results in increased expression of NQO1 mRNA 		CTD PMID:26958860 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage 		ISO 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]] CTD PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]] CTD PMID:32890875 PMID:33396024 NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]] CTD PMID:32890875 NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320 		JBrowse link
G Ptpn3 protein tyrosine phosphatase, non-receptor type 3 multiple interactions ISO lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] CTD PMID:28739874 NCBI chr 5:76,703,687...76,822,584
Ensembl chr 5:76,703,687...76,860,470 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein] CTD PMID:32890875 NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein] CTD PMID:32890875 NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein] CTD PMID:26643609 NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions
decreases response to substance 		ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein]
SNAI1 protein results in decreased susceptibility to lapatinib 		CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr 3:176,667,476...176,671,965 JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]] CTD PMID:33396024 NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA CTD PMID:26958860 NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression 		ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA
lapatinib metabolite results in increased expression of SOD2 mRNA 		CTD PMID:26958860 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein CTD PMID:26643609 NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein] CTD PMID:26643609 PMID:32890875 NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein] CTD PMID:32890875 PMID:33396024 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases response to substance ISO TGFB1 protein results in decreased susceptibility to lapatinib CTD PMID:26643609 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899 		JBrowse link
G Top1 DNA topoisomerase I decreases expression ISO Lapatinib results in decreased expression of TOP1 protein CTD PMID:37788138 NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327 		JBrowse link
G Top2a DNA topoisomerase II alpha decreases expression ISO Lapatinib results in decreased expression of TOP2A protein CTD PMID:37788138 NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 multiple interactions ISO Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]] CTD PMID:33396024 NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965 		JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 decreases activity
multiple interactions 		ISO Lapatinib results in decreased activity of UGT1A3 protein
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid 		CTD PMID:31299240 NCBI chr 9:96,239,019...96,256,264
Ensembl chr 9:96,144,786...96,256,264 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]] CTD PMID:32890875 NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194 		JBrowse link
G Vim vimentin multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein] CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20862
    role 20820
      application 20621
        pharmaceutical 20416
          drug 20416
            antineoplastic agent 18066
              lapatinib 67
Path 2
Term Annotations click to browse term
  CHEBI ontology 20862
    subatomic particle 20860
      composite particle 20860
        hadron 20860
          baryon 20860
            nucleon 20860
              atomic nucleus 20860
                atom 20860
                  main group element atom 20781
                    p-block element atom 20781
                      carbon group element atom 20715
                        carbon atom 20710
                          organic molecular entity 20710
                            organic molecule 20654
                              organic cyclic compound 20404
                                carbocyclic compound 18974
                                  benzenoid aromatic compound 18458
                                    benzenes 18333
                                      fluorobenzenes 6192
                                        monofluorobenzenes 4926
                                          monofluorobenzene 67
                                            lapatinib 67
paths to the root